

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
BURG047--1/KAMSerial No.
09/863,035Applicant
STANISLAW R. BURZYNSKIFiling Date:
May 22, 2001Group:
1614U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A5						
	A6						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B3						
	B4						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>a</i>	C13	Waldbillig, Robert, J., "Pharmacokinetics of ANTINEOPLASTON A-10 and AS2-1 in patients with neoplastic disease" Report filed with FDA March 14, 1997
<i>u</i>	C14	Waldbillig, RJ, Patil, S, and Burzynski, SR "Uptake and intracellular binding of the antineoplastic agents phenylacetic acid (PN) and phenylacetylglutamine (PG): Effects on epigenetic mechanisms of gene regulation and gene expression", Report filed with FDA on May 26, 2004
<i>w</i>	C15	Burzynski, Janicki, Weaver, Jurida, Szymkowski, Khan, and Dolgoplov, "Clinical application of body epigenetic system: multi-targeted therapy for primary brain tumors" Poster at the World Conference on Dosing of Antiinfectives, Nuremberg, Germany, September 9-11, 2004.

EXAMINER:

Alcohol

DATE CONSIDERED:

10/18/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)